Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mei Pharma Inc (NQ: MEIP )

3.070 -0.030 (-0.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mei Pharma Inc

< Previous 1 2 3 4 5 6 7 Next >
MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
Earnings Scheduled For September 26, 2023
Companies Reporting Before The Bell • Ferguson (NYSE:FERG) is estimated to report quarterly earnings at $2.46 per share on revenue of $7.60 billion. 
Via Benzinga
Earnings Outlook For MEI Pharma
Via Benzinga
MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces Results of Special Meeting of Stockholders
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Responds to Anson and Cable Car
From MEI Pharma, Inc.
Via Business Wire
Anson and Cable Car File Preliminary Consent Materials to Remove Entire Board of Directors at MEI Pharma, Inc.
From Anson Funds Management LP
Via GlobeNewswire
MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Postpones Special Meeting of Shareholders
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals
From MEI Pharma, Inc.
Via Business Wire
Infinity Pharmaceuticals Says Second Proxy Advisory Firm Recommends Shareholders To Approve Proposed Merger
Infinity Pharmaceuticals Inc (NASDAQ: INFI) announced further design features of its Phase 2 MARIO-8 study in Squamous Cell Cancer of the  
Via Benzinga
MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Responds to Anson and Cable Car
From MEI Pharma, Inc.
Via Business Wire
Anson Funds and Cable Car Capital Issue Statement Regarding the Inferior Proposed Transaction between MEI Pharma and Infinity Pharmaceuticals
From Anson Funds Management LP
Via GlobeNewswire
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
From Infinity Pharmaceuticals, Inc.
Via Business Wire
MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor
From MEI Pharma, Inc.
Via Business Wire
Anson Funds and Cable Car Capital Issue Statement Regarding MEI Pharma’s Rejection of Their Acquisition Proposal
From Anson Funds Management LP
Via GlobeNewswire
MEI Pharma Board of Directors Rejects Unsolicited Proposal
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal
From MEI Pharma, Inc.
Via Business Wire
Clinical Triumph: MEI Pharma's Voruciclib Demonstrates Encouraging Activity in AML Patients
MEI Pharma Inc (NASDAQ: MEIP) announced an update to the Phase 1 study of voruciclib, an orally administered cyclin-dependent kinase 9 inhibitor, in patients with relapsed and refractory (R/R) acute... 
Via Benzinga
MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
10 Short Squeeze Stocks To Watch: Getty Images, Guardforce AI And 2 Stocks Moving Up Over 1,000 Positions On The Leaderboard
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the... 
Via Benzinga
Here's Why MEI Pharma (MEIP) Stock Is Moving
MEI Pharma (NASDAQ: MEIP) shares are trading lower by roughly 2.54% to $4.68 Monday morning, though rebounding off the session low of $4.30, after the company announced and effected a 1-for-20 reverse... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.